Science In 1992: What Can We Do To Resolve The Uncertainties?

As The Scientist enters its sixth year of publication, it faces a task that its staffers and I engage with energy and optimism. We are determined to further the publication's success to date by continuing to provide a unique news and career information vehicle for all members of the science profession. Our optimism and energy stem, to a great extent, from our healthy 1991 performance as measured against two important periodical publishing benchmarks: circulation and advertising. During the p

Written byEugene Garfield
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Our optimism and energy stem, to a great extent, from our healthy 1991 performance as measured against two important periodical publishing benchmarks: circulation and advertising. During the past year, when many other publishing efforts have fallen victim to these troubled economic times, The Scientist has succeeded in relation to its objectives. Indeed, while some consumer and specialized trade publications have suffered fatal declines in circulation and advertising, we have experienced significant gains in both areas.

We view our strength--and this is confirmed by the communications we receive from readers and advertisers--as a blend of several distinctive factors. We're the only newspaper exclusively addressed to science; the editorial staff is dedicated to writing clearly and with sound ethical motivation about the issues of concern to today's researchers; the focus of every item is pertinent in some way to the career considerations of all readers; and we are aware that good science ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies